 The FDA has accepted for review Acer Therapeutics Inc NASDAQ: ACER and its partner, Relief Therapeutics Holding SAs OTC: RLFTF marketing application for ACER-001 sodium phenylbutyrate for Urea Cycle Disorders UCDs. Related: Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics. 